Immunotherapy in ovarian cancer

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 9, 2012, Pages 1179-1191

  Mantia Smaldone, Gina M ^a   Corr, Bradley ^a   Chu, Christina S ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adoptive transfer; Immunotherapy; Ovarian cancer; Tumor antigen; Vaccine

Indexed keywords

ABAGOVOMAB; ALPHA INTERFERON; BEVACIZUMAB; CANCER VACCINE; CARBOPLATIN; CATUMAXOMAB; CELL LYSATE VACCINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACLIZUMAB; DCVAX; DENDRITIC CELL VACCINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2 VACCINE; GAMMA INTERFERON VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IPILIMUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; MONTANIDE ISA 51; OREGOVOMAB; PACLITAXEL; PEPTIDE VACCINE; PLATINUM DERIVATIVE; PROTEIN P53 VACCINE; RINTATOLIMOD; SYNTHETIC LONG PEPTIDE VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOREDUCTIVE SURGERY; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INNATE IMMUNITY; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE TRANSFER; MELANOMA; MONOTHERAPY; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; SALVAGE THERAPY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; OVARIAN NEOPLASMS;

EID: 84867009579     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.20738     Document Type: Review

References (89)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519-29; PMID:15590954; http://dx.doi.org/10.1056/NEJMra041842.
3. Adams SF, Levine DA, Cadungog MG, Hammond R, Facciabene A, Olvera N, et al. Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 2009; 115:2891-902; PMID:19472394; http://dx.doi.org/10.1002/cncr.24317.
4. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348:203-13; PMID:12529460; http://dx.doi.org/10.1056/ NEJMoa020177.
5. Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003; 9:1517-27; PMID:12684428.
6. Clarke B, Tinker AV, Lee CH, Subramanian S, van de Rijn M, Turbin D, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2009; 22:393-402; PMID:19060844; http://dx.doi.org/10.1038/modpathol.2008.191.
7. Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2012; 124:192-8; PMID:22040834; http://dx.doi.org/10.1016/j.ygyno. 2011.09.039.
8. Kandalaft LE, Powell DJ Jr., Singh N, Coukos G. Immunotherapy for ovarian cancer: what's next? J Clin Oncol 2011; 29:925-33; PMID:21079136; http://dx.doi.org/10.1200/JCO.2009.27.2369.
9. Leffers N, Fehrmann RS, Gooden MJ, Schulze UR, Ten Hoor KA, Hollema H, et al. Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. Br J Cancer 2010; 103:685-92; PMID:20664601; http://dx.doi.org/10.1038/sj.bjc.6605820.
10. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10:942-9; PMID:15322536; http://dx.doi.org/10.1038/nm1093.
11. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102:18538-43; PMID:16344461; http://dx.doi.org/10.1073/ pnas.0509182102.
12. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61:4766-72; PMID:11406550.
13. Chu CS, Kim SH, June CH, Coukos G. Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther 2008; 8:243-57; PMID:18279065; http://dx.doi.org/10.1586/14737140.8.2.243.
14. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol 2011; 29:4828-36; PMID:22042955; http://dx.doi.org/10.1200/JCO.2011. 38.0899.
15. Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 2010; 3:7; PMID:20146807; http://dx.doi.org/10.1186/1756-8722-3-7.
16. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. J Exp Med 1993; 177:1127-34; PMID:8459207; http://dx.doi.org/10.1084/jem.177.4. 1127.
17. Liu B, Nash J, Runowicz C, Swede H, Stevens R, Li Z. Ovarian cancer immunotherapy: opportunities, progresses and challenges. J Hematol Oncol 2010; 3:7; PMID:20146807; http://dx.doi.org/10.1186/1756-8722-3-7.
18. Edwards RP, Gooding W, Lembersky BC, Colonello K, Hammond R, Paradise C, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 1997; 15:3399-407; PMID:9363872.
19. Vlad AM, Budiu RA, Lenzner DE, Wang Y, Thaller JA, Colonello K, et al. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer Immunol Immunother 2010; 59:293-301; PMID:19690855; http://dx.doi.org/10.1007/s00262- 009-0750-3.
20. Thibodeaux SR, Curiel TJ. Immune therapy for ovarian cancer: promise and pitfalls. Int Rev Immunol 2011; 30:102-19; PMID:21557637; http://dx.doi.org/10. 3109/08830185.2011.567361.
21. Nardi M, Cognetti F, Pollera CF, Giulia MD, Lombardi A, Atlante G, et al. Intraperitoneal recombinant alpha-2-interferon alternating with cisplatin as salvage therapy for minimal residual-disease ovarian cancer: a phase II study. J Clin Oncol 1990; 8:1036-41; PMID:2189953.
22. Repetto L, Chiara S, Guido T, Bruzzone M, Oliva C, Ragni N, et al. Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: a pilot study. Anticancer Res 1991; 11:1641-3; PMID:1746921.
23. Kaur T, Slavcev RA, Wettig SD. Addressing the challenge: current and future directions in ovarian cancer therapy. Curr Gene Ther 2009; 9:434-58; PMID:20021329; http://dx.doi.org/10.2174/156652309790031148.
24. Qian HN, Liu GZ, Cao SJ, Feng J, Ye X. The experimental study of ovarian carcinoma vaccine modified by human B7-1 and IFN-gamma genes. Int J Gynecol Cancer 2002; 12:80-5; PMID:11860540; http://dx.doi.org/10.1046/j.1525-1438.2002. 01060.x.
25. Roche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, et al. Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors. Gynecol Oncol 2010; 116:168-72; PMID:19922985; http://dx.doi.org/10. 1016/j.ygyno.2009.10.075.
26. Schmeler KM, Vadhan-Raj S, Ramirez PT, Apte SM, Cohen L, Bassett RL, et al. A phase II study of GM-CSF and rIFN-gamma1b plus carboplatin for the treatment of recurrent, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer. Gynecol Oncol 2009; 113:210-5; PMID:19264351; http://dx.doi.org/10.1016/j.ygyno.2009.02.007.
27. Disis ML, Goodell V, Schiffman K, Knutson KL. Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol 2004; 24:571-8; PMID:15359116; http://dx.doi.org/10. 1023/B:JOCI.0000040928.67495.52.
28. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, et al. Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 2002; 20:2624-32; PMID:12039923; http://dx.doi.org/10.1200/JCO.2002.06.171.
29. Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A 2007; 104:12837-42; PMID:17652518; http://dx.doi.org/10.1073/ pnas.0703342104.
30. Diefenbach CS, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 2008; 14:2740-8; PMID:18451240; http://dx.doi.org/ 10.1158/1078-0432.CCR-07-4619.
31. Rahma OE, Ashtar E, Czystowska M, Szajnik ME, Wieckowski E, Bernstein S, et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunol Immunother 2012; 61:373-84; PMID:21927947; http://dx.doi.org/10.1007/s00262-011-1100-9.
32. Leffers N, Lambeck AJ, Gooden MJ, Hoogeboom BN, Wolf R, Hamming IE, et al. Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial. Int J Cancer 2009; 125:2104-13; PMID:19621448; http://dx.doi.org/10.1002/ijc.24597.
33. Leffers N, Vermeij R, Hoogeboom BN, Schulze UR, Wolf R, Hamming IE, et al. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer. Int J Cancer 2012; 130:105-12; PMID:21328579; http://dx.doi.org/10.1002/ijc.25980.
34. Dohi S, Ohno S, Ohno Y, Takakura M, Kyo S, Soma G, et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Res 2011; 31:2441-5; PMID:21873157.
35. Ohno S, Kyo S, Myojo S, Dohi S, Ishizaki J, Miyamoto K, et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Res 2009; 29:4779-84; PMID:20032435.
36. Sandmaier BM, Oparin DV, Holmberg LA, Reddish MA, MacLean GD, Longenecker BM. Evidence of a cellular immune response against sialyl-Tn in breast and ovarian cancer patients after high-dose chemotherapy, stem cell rescue, and immunization with Theratope STn-KLH cancer vaccine. J Immunother 1999; 22:54-66; PMID:9924700; http://dx.doi.org/10.1097/00002371-199901000-00008.
37. MacLean GD, Reddish MA, Koganty RR, Longenecker BM. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunother Emphasis Tumor Immunol 1996; 19:59-68; PMID:8859725; http://dx.doi.org/10.1097/00002371-199601000-00007.
38. Leffers N, Daemen T, Boezen HM, Melief KJ, Nijman HW. Vaccine-based clinical trials in ovarian cancer. Expert Rev Vaccines 2011; 10:775-84; PMID:21692699; http://dx.doi.org/10.1586/erv.11.42.
39. Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, et al. NY-ESO-1 and LAGE-1 cancertestis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003; 63:6076-83; PMID:14522938.
40. Vermeij R, Leffers N, Hoogeboom BN, Hamming IL, Wolf R, Reyners AK, et al. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study. Int J Cancer 2011; In press; PMID:22139992.
41. Wang B, Kaumaya PT, Cohn DE. Immunization with synthetic VEGF peptides in ovarian cancer. Gynecol Oncol 2010; 119:564-70; PMID:20822802; http://dx.doi.org/10.1016/j.ygyno.2010.07.037.
42. Morse MA, Secord AA, Blackwell K, Hobeika AC, Sinnathamby G, Osada T, et al. MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. Clin Cancer Res 2011; 17:3408-19; PMID:21300761; http://dx.doi.org/10.1158/1078-0432.CCR-10-2614.
43. Chianese-Bullock KA, Irvin WP Jr., Petroni GR, Murphy C, Smolkin M, Olson WC, et al. A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother 2008; 31:420-30; PMID:18391753; http://dx.doi.org/10.1097/CJI.0b013e31816dad10.
44. Sabbatini PJ, Kudryashov V, Ragupathi G, Danishefsky SJ, Livingston PO, Bornmann W, et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer 2000; 87:79-85; PMID:10861456; http://dx.doi.org/10.1002/1097-0215(20000701)87: 1〈79::AIDIJC12〉3.0.CO;2-L.
45. Odunsi KRK, Lele S, et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY-ESO-1 efficiently induces antibody, CD4+ and CD8+ anti tumor immune responses in patients with ovarian cancer. 38th Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. San Diego, CA, USA, 2007.
46. Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008; 14:3060-9; PMID:18483372; http://dx.doi.org/10.1158/1078-0432.CCR-08-0126.
47. Chiang CL, Kandalaft LE, Coukos G. Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 2011; 30:150-82; PMID:21557641; http://dx.doi.org/10.3109/08830185.2011.572210.
48. Buckanovich RJ, Facciabene A, Kim S, Benencia F, Sasaroli D, Balint K, et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008; 14:28-36; PMID:18157142; http://dx.doi.org/10.1038/nm1699.
49. Ehlen TG, Hoskins PJ, Miller D, Whiteside TL, Nicodemus CF, Schultes BC, et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. Int J Gynecol Cancer 2005; 15:1023-34; PMID:16343178; http://dx.doi.org/10.1111/j.1525-1438.2005. 00483.x.
50. Gordon AN, Schultes BC, Gallion H, Edwards R, Whiteside TL, Cermak JM, et al. CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients. Gynecol Oncol 2004; 94:340-51; PMID:15297171; http://dx.doi.org/10.1016/j.ygyno.2004.04.024.
51. Braly P, Nicodemus CF, Chu C, Collins Y, Edwards R, Gordon A, et al. The Immune adjuvant properties of front-line carboplatin-paclitaxel: a randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in advanced ovarian cancer. J Immunother 2009; 32:54-65; PMID:19307994; http://dx.doi.org/10.1097/CJI.0b013e31818b3dad.
52. Berek J, Taylor P, McGuire W, Smith LM, Schultes B, Nicodemus CF. Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J Clin Oncol 2009; 27:418-25; PMID:19075271; http://dx.doi.org/10.1200/JCO.2008.17.8400.
53. Pfisterer J, du Bois A, Sehouli J, Loibl S, Reinartz S, Reuss A, et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 2006; 17:1568-77; PMID:17005631; http://dx.doi.org/10.1093/annonc/mdl357.
54. Reinartz S, Köhler S, Schlebusch H, Krista K, Giffels P, Renke K, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 2004; 10:1580-7; PMID:15014007; http://dx.doi.org/10.1158/1078-0432. CCR-03-0056.
55. Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 2006; 12:5503-10; PMID:17000686; http://dx.doi.org/10.1158/1078-0432.CCR-05-2670.
56. Nicholson S, Bomphray CC, Thomas H, McIndoe A, Barton D, Gore M, et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol Immunother 2004; 53:809-16; PMID:15127236; http://dx.doi.org/10.1007/ s00262-004-0522-z.
57. Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C, et al. Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer 1993; 68:403-6; PMID:8347497; http://dx.doi.org/10.1038/bjc.1993.349.
58. Oei AL, Verheijen RH, Seiden MV, Benigno BB, Lopes A, Soper JT, et al. Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium-90-labeled murine HMFG1 without improvement in overall survival. Int J Cancer 2007; 120:2710-4; PMID:17354223; http://dx.doi.org/10.1002/ijc.22663.
59. Bellone S, Siegel ER, Cocco E, Cargnelutti M, Silasi DA, Azodi M, et al. Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-resistant epithelial ovarian cancer: implications for epithelial cell adhesion molecule-specific immunotherapy. Int J Gynecol Cancer 2009; 19:860-6; PMID:19574774; http://dx.doi.org/10.1111/IGC.0b013e3181a8331f.
60. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010; 127:2209-21; PMID:20473913; http://dx.doi.org/10.1002/ijc.25423.
61. Baumann K, Pfisterer J, Wimberger P, Burchardi N, Kurzeder C, du Bois A, et al. Intraperitoneal treatment with the trifunctional bispecific antibody Catumaxomab in patients with platinum-resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecol Oncol 2011; 123:27-32; PMID:21733566; http://dx.doi.org/10.1016/j.ygyno.2011.06.004.
62. Makhija S, Amler LC, Glenn D, Ueland FR, Gold MA, Dizon DS, et al. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 2010; 28:1215-23; PMID:19901115; http://dx.doi.org/10.1200/JCO.2009.22.3354.
63. Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 2003; 21:283-90; PMID:12525520; http://dx.doi.org/10.1200/JCO.2003. 10.104.
64. Chung MK, Han SS, Roh JK. Synergistic embryotoxicity of combination pyrimethamine and folic acid in rats. Reprod Toxicol 1993; 7:463-8; PMID:8274822; http://dx.doi.org/10.1016/0890-6238(93)90091-K.
65. Molthoff CF, Prinssen HM, Kenemans P, van Hof AC, den Hollander W, Verheijen RH. Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: a phase I study. Cancer 1997; 80(Suppl):2712-20; PMID:9406729; http://dx.doi.org/10.1002/(SICI)1097- 0142(19971215)80:12+〈2712::AIDCNCR50〉3.0.CO;2-B.
66. Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 2010; 16:5288-95; PMID:20855460; http://dx.doi.org/10.1158/1078-0432. CCR-10-0700.
67. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al.; ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365:2484-96; PMID:22204725; http://dx.doi.org/10.1056/NEJMoa1103799.
68. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al.; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365:2473-83; PMID:22204724; http://dx.doi.org/10.1056/NEJMoa1104390.
69. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:5165-71; PMID:18024863; http://dx.doi.org/10.1200/JCO.2007.11.5345.
70. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007; 25:5180-6; PMID:18024865; http://dx.doi.org/10.1200/JCO.2007.12.0782.
71. Leffers N, Daemen T, Helfrich W, Boezen HM, Cohlen BJ, Melief K, et al. Antigen-specific active immunotherapy for ovarian cancer. Cochrane Database Syst Rev:CD007287
72. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008; 8:299-308; PMID:18354418; http://dx.doi.org/10.1038/nrc2355.
73. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005; 23:2346-57; PMID:15800326; http://dx.doi.org/10.1200/JCO.2005.00.240.
74. Aoki Y, Takakuwa K, Kodama S, Tanaka K, Takahashi M, Tokunaga A, et al. Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. Cancer Res 1991; 51:1934-9; PMID:2004379.
75. Lum LG, LeFever AV, Treisman JS, Garlie NK, Hanson JP Jr. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28- costimulated T cells-phase I clinical trial. J Immunother 2001; 24:408-19; http://dx.doi.org/10.1097/00002371-200109000-00003.
76. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006; 12:6106-15; PMID:17062687; http://dx.doi.org/10.1158/1078-0432.CCR-06-1183.
77. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011; 13:98-107; PMID:20849361; http://dx.doi.org/10.3109/14653249.2010.515582.
78. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-26; PMID:17898760; http://dx.doi.org/10.1038/nature06175.
79. Cannon MJ, O'Brien TJ. Cellular immunotherapy for ovarian cancer. Expert Opin Biol Ther 2009; 9:677-88; PMID:19456205; http://dx.doi.org/10.1517/ 14712590902932897.
80. Hernando JJ, Park TW, Kübler K, Offergeld R, Schlebusch H, Bauknecht T. Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002; 51:45-52; PMID:11845259; http://dx.doi.org/10.1007/s00262-001-0255-1.
81. Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother 2012; 61:629-41; PMID:22021066; http://dx.doi.org/10.1007/s00262-011-1081-8.
82. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000; 96:3102-8; PMID:11049990.
83. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A 2008; 105:3005-10; PMID:18287062; http://dx.doi.org/10.1073/ pnas.0712237105.
84. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: reduction of T-suppressor function without depletion of the CD8+ subset. Cancer Res 1987; 47:3317-21; PMID:2953413.
85. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 1982; 155:1063-74; PMID:6460831; http://dx.doi.org/10.1084/jem.155.4. 1063.
86. Ercolini AM, Ladle BH, Manning EA, Pfannenstiel LW, Armstrong TD, Machiels JP, et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the anti-tumor immune response. J Exp Med 2005; 201:1591-602; PMID:15883172; http://dx.doi.org/10.1084/jem.20042167.
87. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466.
88. Hodi FS, Mihm MC, Soiffer RJ, Haluska FG, Butler M, Seiden MV, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003; 100:4712-7; PMID:12682289; http://dx.doi.org/10.1073/pnas.0830997100.
89. Alagkiozidis I, Facciabene A, Carpenito C, Benencia F, Jonak Z, Adams S, et al. Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. J Transl Med 2009; 7:104; PMID:20003308; http://dx.doi.org/10.1186/1479-5876-7-104.